-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Pancreatic Ductal Adenocarcinoma Drug Details: Onvansertib fumarate (PCM-075) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Refractory Acute Myeloid Leukemia Drug Details: Onvansertib fumarate (PCM-075) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Onvansertib fumarate (PCM-075)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onvansertib Fumarate in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Onvansertib Fumarate in Small-Cell Lung Cancer Drug Details:Onvansertib fumarate (PCM-075) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC) Drug Details:Onvansertib fumarate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onvansertib Fumarate in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Onvansertib Fumarate in Colorectal Cancer Drug Details:Onvansertib fumarate (PCM-075) is under development...
-
Company Profile
Cardiff Oncology Inc – Company Profile
Cardiff Oncology Inc (Cardiff Oncology), formerly Trovagene Inc is a clinical-stage biotechnology company that focuses on developing drugs which target cell division (mitosis) using precision cancer medicine (PCM) approach for the treatment of hematologic and solid tumor cancers. The company lead product candidate is Onvansertib (previously known as PCM-075), an oral and adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1) enzyme. The company is being developed in combination with chemotherapies and targeted therapeutics for treatment of metastatic pancreatic...
Add to Basket